CrushSCI.com
220.7平均天数
195中位天数
15最短天数
428最长天数
952025发文量

Paper Review Records

全部论文审稿周期

19 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

195 天

Formulation-Specific Safety Issues of HIV Pre-exposure Prophylaxis Drugs: A Disproportionality Analysis of the FAERS Database

作者
Davide Rozza; Elisabetta Poluzzi; Ippazio Cosimo Antonazzo; Angela Boccia; Marco Paccini; Fortuna Gallucci; Domenico Ponticelli; Giulio Geraci; Fernando Agüero; Giampiero Mazzaglia; Lorenzo Giovanni Mantovani; Emanuel Raschi; Pietro Ferrara展开收起
作者单位
1. Center for Public Health Research, University of Milan–Bicocca, Monza, Italy; 2. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 3. Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy; 4. Clinica Montevergine SpA, Mercogliano, Italy; 5. Department of Medicine and Surgery, “Kore” University of Enna, Enna, Italy; 6. Internal Medicine Unit, Hospital Umberto I, ASP Enna, Enna, Italy; 7. Preventive Medicine Unit, Hospital Universitari General de Catalunya, Quirónsalud, Barcelona, Spain; 8. Laboratory of Public Health, IRCCS Istituto Auxologico Italiano, Milan, Italy展开收起
PDF源文件 DOI 网页
258 天

Statin Use and Arterial Calcification in the General Population: A Longitudinal Analysis and a Negative Control Population

作者
Mitra Nekouei Shahraki; Jeremy A Labrecque; Fariba Ahmadizar; Bruno H Stricker; Maryam Kavousi; Daniel Bos展开收起
作者单位
1. Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Department of Data Science and Biostatistics, Julius Global Health, University Medical Center Utrecht, Utrecht, The Netherlands; 3. Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands展开收起
PDF源文件 DOI 网页
173 天

Pharmacokinetics and Tolerability of Fexinidazole in Subjects with Hepatic Impairment

作者
Matthieu Gassiot; Jean Pierre Beaucire; Sophie Hays; Sarah Lezzar; Céline Beauchard; Eric Sultan展开收起
作者单位
1. Sanofi R&D, Montpellier, France; 2. Sanofi, Gentilly, France; 3. Biotrial, Rennes, France; 4. PhinC Development, Massy, France; 5. Foundation S, The Sanofi Collective, Gentilly, France展开收起
PDF源文件 DOI 网页
179 天

Modeling Cancer Outcomes and Economic Impact of the Anti-PD-1/PD-L1 Immunotherapy in the Gulf: United Arab Emirates, Oman, and Kuwait

作者
Humaid O. Al-Shamsi; Mohamed Farghaly; Ammar Abdaljalil; Abdulwahab Al-Tourah; Chana Saad; Youmna Bassil; Ghadah Albassam; Rami Nimer; Monika Naroz; Omar El-Badry; Rony Akel展开收起
作者单位
1. Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates; 2. Dubai Health Insurance Corporation, Dubai, United Arab Emirates; 3. Sheikh Shakhboot Medical City, Abu Dhabi, United Arab Emirates; 4. Kuwait Cancer Control Center, Kuwait City, Kuwait; 5. Center of Clinical, Health Economics, and Outcomes Research (CCHO-FZ-LLC), Dubai, United Arab Emirates; 6. MSD KSA GmbH, Riyadh, Saudi Arabia; 7. MSD IDEA Middle East, Dubai, United Arab Emirates展开收起
PDF源文件 DOI 网页
190 天

Efficacy and Safety of Ustekinumab Biosimilars in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-analysis

作者
Mohsin Rashid; Awon Muhammad; Eeraj Saeed; Ali Akram Qureshi; Mohammad Maheer Mubashir; Mohammad Waqas bin Waheed; Muhammad Abdullah Yasin; Muhammad Abdullah; Ahsan Rashid; Zainab Zubair展开收起
作者单位
1. Department of Medicine, King Edward Medical University, Lahore, Pakistan; 2. Department of Medicine, District Headquarters Hospital, Jhelum, Pakistan; 3. Department of Medicine, Fatima Jinnah Medical University, Lahore, Pakistan展开收起
PDF源文件 DOI 网页
419 天

Cost Effectiveness of Teriparatide for Postmenopausal Osteoporosis: A Systematic Review

作者
Mohammad Alimoradnori; Ali Abutorabi; Mozhdeh Zabihiyeganeh; Jalal Arabloo; Reza Jahanghiri展开收起
作者单位
1. Department of Health Economics, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran; 2. Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran; 3. Department of Orthopedics, Bone and Joint Reconstruction Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; 4. Hospital Management Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran, Iran展开收起
PDF源文件 DOI 网页

FAQ

CLINICAL DRUG INVESTIGATION审稿要多久?

截至2026-11-19,CrushSCI 收录了 CLINICAL DRUG INVESTIGATION 的 19 篇完整审稿记录。最快一篇从收稿到录用用了 15 天(Deuruxolitinib: New Approval,2026-04-29 收稿,2026-05-14 录用),最慢一篇用了 428 天;平均 220.7 天,中位数 195 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。